HomeNewsBusinessLupin Q1 PAT may dip 79.8% YoY to Rs 109.5 cr: Prabhudas Lilladher
Trending Topics
RBI MPC Meeting
Sensex Live
Home Loan Rates
Fixed Deposit Interest Rates
Gold Rate Today

Lupin Q1 PAT may dip 79.8% YoY to Rs 109.5 cr: Prabhudas Lilladher

Net Sales are expected to decrease by 0.7 percent Y-o-Y (up 9.2 percent Q-o-Q) to Rs 4,240.2 crore, according to Prabhudas Lilladher.

Broker Research
July 08, 2022 / 17:36 IST
Story continues below Advertisement
Remove Ad
Lupin: Lupin receives USFDA nod for Paliperidone tablets that used to treat schizophrenia. The pharma company has received approval from US FDA for its Abbreviated New Drug Application (ANDA) - Paliperidone extended-release tablets. The drug is a generic equivalent of Invega extended-release tablets of Janssen Research and Development, LLC. The product will be manufactured at Lupin's facility in Goa. The drug had estimated annual sales of $152 million in the US as per IQVIA MAT March 2022 data. The drug is used in the treatement of schizophrenia, a mental disorder.
Lupin: Lupin receives USFDA nod for Paliperidone tablets that used to treat schizophrenia. The pharma company has received approval from US FDA for its Abbreviated New Drug Application (ANDA) - Paliperidone extended-release tablets. The drug is a generic equivalent of Invega extended-release tablets of Janssen Research and Development, LLC. The product will be manufactured at Lupin's facility in Goa. The drug had estimated annual sales of $152 million in the US as per IQVIA MAT March 2022 data. The drug is used in the treatement of schizophrenia, a mental disorder.

Prabhudas Lilladher has come out with its first quarter (April-June’ 22) earnings estimates for the Healthcare sector. The brokerage house expects Lupin to report net profit at Rs 109.5 crore down 79.8% year-on-year (down 121.1% quarter-on-quarter).

Net Sales are expected to decrease by 0.7 percent Y-o-Y (up 9.2 percent Q-o-Q) to Rs 4,240.2 crore, according to Prabhudas Lilladher.

Story continues below Advertisement
Remove Ad

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 59.4 percent Y-o-Y (up 66.4 percent Q-o-Q) to Rs 376.7 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Follow Us On: Facebook twitter instagram linkedin youtube
News
Business New Market New Stocks Income Tax Calculator Election Schedule 2024 India News Economy Mutual Funds Personal Finance IPO News Startups New USA Elections New
Features
Gold Rate Today Silver Rate Today Trending News Startups New National News MC Videos MC You Tube
Tools
SIP Calculator 2 SIP Calculator 3 SIP Calculator 1 New SIP Calculator 4
Specials
PowerYourTrade Master Your Money Game Changers
Network 18 Sites
News18 Firstpost CNN News18 CNBC TV18 Forbes History TV18
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker Fixed Deposits Fixed Deposit Comparison Fixed Income Account Aggregator
Quick Links
About Us New Contact Us Advisory Alert New Advertise with Us New Disclaimer Privacy Policy Cookie Policy Terms & Conditions Careers Financial Terms (Glossary) Analytical & Information Tool New
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.